Published in J Exp Med on March 01, 1988
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci U S A (1992) 2.73
Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51
Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc Natl Acad Sci U S A (2000) 2.49
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors. J Immunol (1991) 1.77
IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers. J Clin Invest (2008) 1.71
Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun (1995) 1.69
Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Exp Med (1991) 1.66
Modulation of cytokine-induced HIV gene expression by competitive binding of transcription factors to the coactivator p300. EMBO J (1998) 1.56
Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci U S A (1991) 1.29
Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc Natl Acad Sci U S A (1992) 1.29
The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med (1988) 1.27
Tumor necrosis factor/cachectin. Induction of hemorrhagic necrosis in normal tissue requires the fifth component of complement (C5). J Exp Med (1988) 1.16
The effect of Mycobacterium tuberculosis on the susceptibility of human cells to the stimulatory and toxic effects of tumour necrosis factor. Immunology (1992) 1.16
Inhibition of NF-kappaB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or oxaliplatin. J Biol Chem (2010) 1.10
Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci U S A (1993) 1.06
Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med (1993) 0.96
A model for the investigation of factors influencing haemorrhagic necrosis mediated by tumour necrosis factor in tissue sites primed with mycobacterial antigen preparations. Clin Exp Immunol (1992) 0.95
Role of TLR2-dependent inflammation in metastatic progression. Ann N Y Acad Sci (2011) 0.94
Pre-conditioning cryosurgery: cellular and molecular mechanisms and dynamics of TNF-α enhanced cryotherapy in an in vivo prostate cancer model system. Cryobiology (2010) 0.94
Targeting the tumor microenvironment to enhance antitumor immune responses. Oncotarget (2015) 0.89
Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma. World J Gastroenterol (2003) 0.89
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Transcriptional control of viral gene therapy by cisplatin. J Clin Invest (2002) 0.85
A model for cancer-suppressive inflammation. Oncoimmunology (2012) 0.85
Cardamonin sensitizes tumour cells to TRAIL through ROS- and CHOP-mediated up-regulation of death receptors and down-regulation of survival proteins. Br J Pharmacol (2012) 0.84
Interleukin 1-induced, T cell-mediated regression of immunogenic murine tumors. Requirement for an adequate level of already acquired host concomitant immunity. J Exp Med (1988) 0.84
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor. J Immunol (1992) 0.81
Cancer as a Proinflammatory Environment: Metastasis and Cachexia. Mediators Inflamm (2015) 0.79
Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B. World J Gastroenterol (2005) 0.79
Proteomic analysis of osteogenic sarcoma: association of tumour necrosis factor with poor prognosis. Int J Exp Pathol (2010) 0.79
Clostridial spores for cancer therapy: targeting solid tumour microenvironment. J Toxicol (2012) 0.78
Roles for tumor necrosis factor and gamma interferon in resistance to enteric listeriosis. Infect Immun (1998) 0.77
Immunohistochemical Characterization of Antioxidant Enzymes in Human Breast Cancer. Pathol Oncol Res (1997) 0.77
Effect of tumour necrosis factor and lipid A on functional and structural vascular volume in solid murine tumours. Br J Cancer (1990) 0.76
TNF Neutralization Results in the Delay of Transplantable Tumor Growth and Reduced MDSC Accumulation. Front Immunol (2016) 0.75
Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer. Br J Cancer (2003) 0.75
Glucocorticoid-mediated inhibition of endotoxin-induced intratumor tumor necrosis factor production and tumor hemorrhagic necrosis and regression. J Exp Med (1989) 0.75
Tumor necrosis factor links chronic obstructive pulmonary disease and K-ras mutant lung cancer through induction of an immunosuppressive pro-tumor microenvironment. Oncoimmunology (2016) 0.75
Endotoxin-induced tumor necrosis factor alpha synthesis in murine embryo fibroblasts. Infect Immun (1993) 0.75
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma. Transl Oncol (2017) 0.75
The effect of adrenalectomy and dexamethasone on interleukin-1 alpha induced responses in RIF-1 tumours. Br J Cancer (1990) 0.75
Anti-tumor action of tumor necrosis factor against Bomirski Ab melanoma in hamsters. Arch Immunol Ther Exp (Warsz) (2007) 0.75
Tumor reductive therapies and antitumor immunity. Oncotarget (2017) 0.75
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 19.41
Shock and tissue injury induced by recombinant human cachectin. Science (1986) 16.24
Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature (1985) 13.04
Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature (1986) 11.09
Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature (1985) 7.22
Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med (1986) 6.32
Molecular cloning of the complementary DNA for human tumor necrosis factor. Science (1985) 6.18
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
Similarities of the anti-tumour actions of endotoxin, lipid A and double-stranded RNA. Br J Cancer (1973) 4.65
Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor. Nature (1985) 3.59
Molecular cloning of mouse tumour necrosis factor cDNA and its eukaryotic expression. Nucleic Acids Res (1985) 3.09
Corynebacterium parvum as the priming agent in the production of tumor necrosis factor in the mouse. J Natl Cancer Inst (1977) 2.15
The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med (1978) 1.96
Production and characterization of anti-murine interferon-gamma sera. J Interferon Res (1983) 1.73
Actions of tumor necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition, and cytotoxicity. J Natl Cancer Inst (1986) 1.68
Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol (1987) 1.49
The immunological basis of endotoxin-induced tumor regression. Requirement for a pre-existing state of concomitant anti-tumor immunity. J Exp Med (1978) 1.43
The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J Exp Med (1988) 1.27
Subtherapeutic numbers of tumour-sensitized, L3T4+, Ly 1+2- T cells are needed for endotoxin to cause regression of an established immunogenic tumour. Immunology (1987) 1.06
The therapeutic significance of concomitant antitumor immunity. II. Passive transfer of concomitant immunity with Ly-1+2- T cells primes established tumors in T cell-deficient recipients for endotoxin-induced regression. Cancer Immunol Immunother (1984) 0.98
Synergistic action of human recombinant tumor necrosis factor with endotoxins or nontoxic poly A:U against solid Meth A tumors in mice. Cancer Immunol Immunother (1987) 0.94
Complete nucleotide sequence of SV40 DNA. Nature (1978) 24.07
Complete structure of the hemagglutinin gene from the human influenza A/Victoria/3/75 (H3N2) strain as determined from cloned DNA. Cell (1980) 14.28
Preferential codon usage in prokaryotic genes: the optimal codon-anticodon interaction energy and the selective codon usage in efficiently expressed genes. Gene (1982) 11.99
Plasmid vectors for high-efficiency expression controlled by the PL promoter of coliphage lambda. Gene (1981) 9.44
Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell (1991) 8.75
Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. J Immunol (1986) 8.22
Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc Natl Acad Sci U S A (1997) 7.90
Studies on in vitro transformation by DNA and DNA fragments of human adenoviruses and simian virus 40. Cold Spring Harb Symp Quant Biol (1975) 7.76
Importance of thymus-derived lymphocytes in cell-mediated immunity to infection. Cell Immunol (1973) 7.68
Preparative two-dimensional polyacrylamide gel electrophoresis of 32 P-labeled RNA. Anal Biochem (1972) 7.53
The relative importance of blood monocytes and fixed macrophages to the expression of cell-mediated immunity to infection. J Exp Med (1970) 7.13
Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. Nature (1976) 6.36
Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science (2000) 6.19
Cellular mediators of anti-Listeria immunity as an enlarged population of short lived, replicating T cells. Kinetics of their production. J Exp Med (1973) 5.94
Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci U S A (1986) 5.83
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47
Cleavage map of the simian-virus-40 genome by the restriction endonuclease III of Haemopholus aegyptius. Eur J Biochem (1976) 5.31
Antigenic drift between the haemagglutinin of the Hong Kong influenza strains A/Aichi/2/68 and A/Victoria/3/75. Nature (1980) 5.25
Nucleotide sequence of the gene coding for the bacteriophage MS2 coat protein. Nature (1972) 5.05
Recombinant human tumor necrosis factor increases mRNA levels and surface expression of HLA-A,B antigens in vascular endothelial cells and dermal fibroblasts in vitro. Proc Natl Acad Sci U S A (1986) 5.03
Ia expression by vascular endothelium is inducible by activated T cells and by human gamma interferon. J Exp Med (1983) 4.92
Improved plasmid vectors with a thermoinducible expression and temperature-regulated runaway replication. Gene (1983) 4.87
A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med (1999) 4.82
The relative importance of T cell subsets in immunity and immunopathology of airborne Mycobacterium tuberculosis infection in mice. J Exp Med (2001) 4.50
Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci U S A (1984) 4.43
Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia. J Exp Med (1993) 4.30
Nucleotide sequence of the Hind-C fragment of simian virus 40 DNA. Comparison of the 5'-untranslated region of wild-type virus and of some deletion Mutants. Eur J Biochem (1979) 4.24
Lymphocytes recognize human vascular endothelial and dermal fibroblast Ia antigens induced by recombinant immune interferon. Nature (1983) 4.16
Isolation and structure of a human fibroblast interferon gene. Nature (1980) 4.16
Neutrophils are essential for early anti-Listeria defense in the liver, but not in the spleen or peritoneal cavity, as revealed by a granulocyte-depleting monoclonal antibody. J Exp Med (1994) 4.16
Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med (1998) 4.08
Cellular kinetics associated with the development of acquired cellular resistance. J Exp Med (1969) 3.94
Cytotoxic activity of tumor necrosis factor is mediated by early damage of mitochondrial functions. Evidence for the involvement of mitochondrial radical generation. J Biol Chem (1992) 3.76
The concept of the activated macrophage. J Immunol (1978) 3.69
Two tumour necrosis factor receptors: structure and function. Trends Cell Biol (1995) 3.67
Evidence for tumour necrosis factor/cachectin production in cancer. Lancet (1987) 3.66
Structural analysis of the sequence coding for an inducible 26-kDa protein in human fibroblasts. Eur J Biochem (1986) 3.63
Early gamma interferon production by natural killer cells is important in defense against murine listeriosis. Infect Immun (1991) 3.59
Requirement of an ICE/CED-3 protease for Fas/APO-1-mediated apoptosis. Nature (1995) 3.59
Early pathogenesis of infection in the liver with the facultative intracellular bacteria Listeria monocytogenes, Francisella tularensis, and Salmonella typhimurium involves lysis of infected hepatocytes by leukocytes. Infect Immun (1992) 3.52
Molecular cloning of human interleukin 2 cDNA and its expression in E. coli. Nucleic Acids Res (1983) 3.44
The 3' untranslated region of the human interferon-beta mRNA has an inhibitory effect on translation. Proc Natl Acad Sci U S A (1987) 3.37
Virulence ranking of some Mycobacterium tuberculosis and Mycobacterium bovis strains according to their ability to multiply in the lungs, induce lung pathology, and cause mortality in mice. Infect Immun (1995) 3.31
The mitotic potential of fixed phagocytes in the liver as revealed during the development of cellular immunity. J Exp Med (1969) 3.30
The histogenesis of immunologically committed lymphocytes. Cell Immunol (1972) 3.29
Secondary structure of mRNA and efficiency of translation initiation. Gene (1980) 3.18
Micro thin-layer techniques for rapid sequence analysis of 32P-labeled RNA: double digestion and pancreatic ribonuclease analyses. Anal Biochem (1977) 3.18
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med (1980) 3.17
T cell dependence of macrophage activation and mobilization during infection with Mycobacterium tuberculosis. Infect Immun (1974) 3.16
Simple, efficient in vitro synthesis of capped RNA useful for direct expression of cloned eukaryotic genes. Nucleic Acids Res (1982) 3.12
Activation of cultured human endothelial cells by recombinant lymphotoxin: comparison with tumor necrosis factor and interleukin 1 species. J Immunol (1987) 3.06
Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF. EMBO J (1993) 2.98
p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem (1998) 2.97
Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am J Pathol (1986) 2.95
Resistance ranking of some common inbred mouse strains to Mycobacterium tuberculosis and relationship to major histocompatibility complex haplotype and Nramp1 genotype. Immunology (1998) 2.91
The action of cortisone acetate on cell-mediated immunity to infection. Suppression of host cell proliferation and alteration of cellular composition of infective foci. J Exp Med (1971) 2.89
Lysis gene expression of RNA phage MS2 depends on a frameshift during translation of the overlapping coat protein gene. Nature (1982) 2.77
Studies on the bacteriophage MS2. The untranslated 5'-terminal nucleotide sequence preceding the first cistron. Eur J Biochem (1971) 2.76
Analysis of 32P-labeled bacteriophage MS2 RNA by a mini-fingerprinting procedure. Anal Biochem (1976) 2.67
Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc Natl Acad Sci U S A (1995) 2.67
The p38/RK mitogen-activated protein kinase pathway regulates interleukin-6 synthesis response to tumor necrosis factor. EMBO J (1996) 2.64
Neutrophils are critical for host defense against primary infection with the facultative intracellular bacterium Francisella tularensis in mice and participate in defense against reinfection. Infect Immun (1994) 2.61
Neutrophil-mediated dissolution of infected host cells as a defense strategy against a facultative intracellular bacterium. J Exp Med (1991) 2.55
Nature of "memory" in T-cell mediated antibacterial immunity: cellular parameters that distinguish between the active immune response and a state of "memory". Infect Immun (1975) 2.50
A human high affinity interleukin-5 receptor (IL5R) is composed of an IL5-specific alpha chain and a beta chain shared with the receptor for GM-CSF. Cell (1991) 2.49
Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells. J Exp Med (1984) 2.44
Genes for the tumor necrosis factors alpha and beta are linked to the human major histocompatibility complex. Proc Natl Acad Sci U S A (1986) 2.42
Is amyloidogenesis during Alzheimer's disease due to an IL-1-/IL-6-mediated 'acute phase response' in the brain? Immunol Today (1991) 2.41
Heterogeneity of the 5' terminus of late mRNA induced by a viable simian virus 40 deletion mutant. J Virol (1979) 2.40
Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes. Nature (1987) 2.31
B cell growth modulating and differentiating activity of recombinant human 26-kd protein (BSF-2, HuIFN-beta 2, HPGF). EMBO J (1987) 2.30
Cloned human interferon-gamma, but not interferon-beta or -alpha, induces expression of HLA-DR determinants by fetal monocytes and myeloid leukemic cell lines. J Immunol (1984) 2.26
Nucleotide sequence deletions within the coding region for small-t antigen of simian virus 40. J Virol (1979) 2.23
A micromethod for base analysis of 32P-labeled oligoribonulcleotides. Anal Biochem (1977) 2.21
On the mechanism of T cell-independent anti-Listeria resistance in nude mice. J Immunol (1980) 2.20
Evidence for the direct involvement of DNA replication origin in synthesis of late SV40 RNA. Nature (1982) 2.20
Binding of human tumor necrosis factor to high affinity receptors on HeLa and lymphoblastoid cells sensitive to growth inhibition. J Biol Chem (1985) 2.18
Nature of "memory" in T-cell-mediated antibacterial immunity: anamnestic production of mediator T cells. Infect Immun (1975) 2.16
Bacteriophage Ms2 RNA: nucleotide sequence of the end of the a protein gene and the intercistronic region. Nat New Biol (1973) 2.15
Evidence inconsistent with a role for the Bcg gene (Nramp1) in resistance of mice to infection with virulent Mycobacterium tuberculosis. J Exp Med (1996) 2.14
Dual signaling of the Fas receptor: initiation of both apoptotic and necrotic cell death pathways. J Exp Med (1998) 2.11
The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci U S A (1987) 2.10
Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster ovary cells. Proc Natl Acad Sci U S A (1983) 2.09
A-protein gene of bacteriophage MS2. Nature (1975) 2.08
The uptake of particulate antigens. J Reticuloendothel Soc (1968) 2.07
Inflammatory lymphocyte in cell-mediated antibacterial immunity: factors governing the accumulation of mediator T cells in peritoneal exudates. Infect Immun (1974) 2.02
Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res (1982) 2.01
Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. J Immunol (1986) 2.00
Complete DNA sequence of yeast chromosome II. EMBO J (1994) 1.97
Complete structure of A/duck/Ukraine/63 influenza hemagglutinin gene: animal virus as progenitor of human H3 Hong Kong 1968 influenza hemagglutinin. Cell (1981) 1.96
The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med (1978) 1.96
The action of cortisone acetate on cell-mediated immunity to infection: histogenesis of the lymphoid cell response and selective elimination of committed lymphocytes. Cell Immunol (1972) 1.95
Characterization of the 5'-terminal cap structures of early simian virus 40 mRNA. J Virol (1980) 1.95
T-cell-mediated concomitant immunity to syngeneic tumors. I. Activated macrophages as the expressors of nonspecific immunity to unrelated tumors and bacterial parasites. J Exp Med (1977) 1.93
Human TNF mutants with selective activity on the p55 receptor. Nature (1993) 1.91
Resolution of primary murine listeriosis and acquired resistance to lethal secondary infection can be mediated predominantly by Thy-1+ CD4- CD8- cells. J Infect Dis (1991) 1.90
Advantages of measuring changes in the number of viable parasites in murine models of experimental cutaneous leishmaniasis. Infect Immun (1983) 1.90